Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 597,300 shares, an increase of 30.7% from the December 15th total of 457,100 shares. Approximately 22.4% of the shares of the company are short sold. Based on an average daily volume of 421,900 shares, the days-to-cover ratio is presently 1.4 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Trading Up 5.6 %

Shares of NASDAQ:ALGS opened at $31.73 on Thursday. The company has a 50 day moving average of $29.86 and a 200 day moving average of $17.73. The stock has a market cap of $113.85 million, a P/E ratio of -2.38 and a beta of 2.50. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The firm had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same quarter last year, the firm earned ($10.25) earnings per share. On average, equities analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Acadian Asset Management LLC lifted its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 26.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 829,485 shares of the company’s stock after purchasing an additional 171,490 shares during the quarter. Acadian Asset Management LLC owned 1.06% of Aligos Therapeutics worth $289,000 at the end of the most recent quarter. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).